CN101703482A - Galanthamine long-acting release injectable microsphere composite and preparation method thereof - Google Patents
Galanthamine long-acting release injectable microsphere composite and preparation method thereof Download PDFInfo
- Publication number
- CN101703482A CN101703482A CN200910230292A CN200910230292A CN101703482A CN 101703482 A CN101703482 A CN 101703482A CN 200910230292 A CN200910230292 A CN 200910230292A CN 200910230292 A CN200910230292 A CN 200910230292A CN 101703482 A CN101703482 A CN 101703482A
- Authority
- CN
- China
- Prior art keywords
- microsphere
- galantamine
- preparation
- galanthamine
- long
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses galanthamine microspheres which contain 5-40wt% of basic group of galanthamine and 60-95wt % of polylactic acid/hydroxyacetic acid copolymer. The invention also provides a galanthamine long-acting release injectable microsphere composite which comprises the following components by weight percent: 60-90% of galanthamine microspheres, 5-25% of frozen dry proppant, 0.5-5% of suspending agent, 0.5-5% of wetting agent and 1-25% of osmotic pressure regulator. The invention combines the vibration nozzle method with the emulsion process (O/W)-solvent evaporation method so that the method has the advantage that the droplet-generating speed is fast, the efficiency is high, the containers used in preparation are easy to use in the aseptic operation, the production process can be carried out continuously, the technology is applicable to scale-up application, etc.
Description
Technical field
The present invention relates to a kind of injectable microsphere composite and preparation method, more particularly, relate to a kind of biodegradable galanthamine long-acting injection sustained-release microspherical composition and preparation method.
Background technology
Galantamine belongs to the competitive cholinesterase inhibitor of the second filial generation, can see through blood brain barrier, and interrupted neuromuscular conduction is recovered, and improves the palsy of various peripheral nerve muscular disorders.Be used for the treatment of myasthenia gravis in early days, the discovered in recent years galantamine can significantly improve gerontal patient's memory, be mainly used in that treatment is slight, moderate and severe Alzheimer's disease (AD), evident in efficacy after 6～8 weeks of medication, this product is applicable to benign memory deficits, improves that the patient points to that memory, learning by association, image are recalled, random shape is re-recognized and ability such as portrait memory.The dysmnesia that dementia patients and brain organic pathological changes the are caused effect that also has clear improvement.The common formulations of galantamine has tablet (5mg/ sheet), capsule (5mg/ grain) and injection (1mg, 2.5mg, 5mg/ml).Because the dissolubility of galantamine is relatively poor, thus be made into hydrobromate usually, to increase its dissolubility.The dosage form of having studied has oral liquid, injection, ordinary tablet, dispersible tablet, slow releasing tablet, capsule, ointment etc.Usages such as the dosage of common formulations, the course of treatment are as follows: (capsule, tablet) 5mg/ grain, 4 times/day; Injection: intramuscular injection or subcutaneous injection, each 2.5-10mg, 1 time/day, 1 the 2-6 week course of treatment.Therefore, because the biological half-life of galantamine is shorter, be about 5 hours, oral administration every day needs 4 times, and administration is frequent, and clinical application is very inconvenient, and AD patient's memory, judgement, ability of thinking decline, forfeiture, multiple dosing, the compliance of treatment can not get ensureing, the phenomenon that patient misses or obeys more often occurs.Injection intramuscular injection or subcutaneous administration, 1 time/day, the course of treatment is long, and drug administration by injection treatment inconvenience causes more misery to the patient.Conventional formulation such as oral formulations and injection of solution agent, except the frequent inconvenience of administration, the drug level peak valley phenomenon also is a problem.It is reported that because blood drug level is too high, excessively acetylcholine esterase inhibition will cause untoward reaction such as tangible digestive tract and vascular smooth muscle, its untoward reaction strengthens along with the increase of dosage.
Therefore, the slow releasing preparation of preparation galantamine can reduce administration number of times, improves compliance of patients, reduces the untoward reaction that the fluctuation of blood medicine causes.The research of the slow releasing preparation of galantamine at present, bibliographical information is a slow releasing tablet, as Liu Wei (Liu Wei, flat its energy. the development of Galantamin hydrobromide sustained-release sheet [J]. Jiangsu pharmacy and clinical research, 2006; 14 (4): be main slow-release material 215-217) with glyceryl monostearate, Eudragit E udragit L100-55, the preparation slow releasing tablet, the Galantamin hydrobromide sustained-release sheet presents the good slow release characteristic in 24h as a result.Chen Ang, He Fen (Chen Ang, He Fen. the pastille resin surface is modified legal system and is equipped with galantamine oral sustained release suspension [J]. Chinese Journal of Pharmaceuticals, 2007,38 (3): 227-232) adopt ion exchange absorption technology, modify the resin surface that is combined with galanthamine hydrobromide with acrylic resin RS100, make slow-release suspension, but slow release 12h.Oral slow releasing preparation slow-release time is generally 12-24h, and concerning patient AD, administration number of times still is more, easily the phenomenon that misses or obey more.Therefore, relatively, long-acting slow-release preparation reaches the preparation of two weeks to month as the slow release cycle, should be used for from actual therapeutic, can greatly reduce frequency, improve patient's treatment compliance, reduce the treatment cost, can finely satisfy the clinical treatment demand of AD, have good application potential.
Biodegradable material is the new material that obtains broad research and application in recent years at home and abroad, comprise polylactic acid (PLA), polylactic acid/hydroxy acetate multipolymer (PLGA), polycaprolactone (PCL) etc. polylactic acid series material is good long-acting slow-release material, has certain mechanical strength, histocompatibility is good, no immunoreation, biodegradable in vivo is a lactic acid, hydroxyacetic acid, finally be degraded to carbon dioxide and water, therefore implant or inject subcutaneous, need not operation behind the muscle takes out. adopt PLGA 1 month the leuprorelin acetate long-acting slow-release microsphere (trade name: enantone of slow release of successfully developing and go on the market from Japanese military field drugmaker, LeupDepot) since, polylactic acid-based material has obtained increasingly extensive application in the continuous release microsphere drug-supplying system. and long-acting slow-release microsphere technology is the sophisticated technology in the pharmaceutical preparation, has become the focus of domestic and international preparation research and development. and the technological means that adopts Biodegradable material PLGA to prepare the continuous release microsphere of drug administration by injection is admitted widely.
Adopt biodegradable polymer, packaging medicine is prepared into micro-balloon injection, the size of microsphere is generally at 100 μ m, with the form packing of lyophilized injectable powder, adding sterilized water for injection or normal saline are made disperse medium before using, slight jolting, can form stable suspensoid, adopt conventional syringe approach drug administration by injection subcutaneous or intramuscular to get final product, syringeability is good, does not need operation to implant.Microsphere is after subcutaneous, intramuscular injection administration, along with slow corrosion, the biodegradation of material at the drug administration by injection position, drug release comes out, absorb and enter blood circulation, therefore infiltration rate is slow, and can come control drug release speed according to the selection of materials such as the degree of polymerization of material, molecular weight, monomeric ratio, thereby can play the administration purpose of long-acting slow-release in vivo.At present, do not see the research report of galanthamine long-acting release micro-balloon injection as yet, therefore research and develop this novel form and have excellent research value.
The preparation technology of long-acting slow-release micro-balloon injection uses stirring and emulsifying (O/W, W/O or W/O/W)-solvent evaporation method (Emulsion-solvent evaporation method), spray drying method (Spray drying method), supercritical fluid technology sedimentation (Supercritical fluid CO always
2Anti-solvent method) etc.But the preparation method of these microspheres commonly used exists one of common shortcoming: the particle diameter of microsphere can not be well controlled, so the volume difference in size of microsphere is big, and particle size distribution is wide.At this problem, conventional method is the screening method that adopts final microsphere, screen out the excessive or too small microsphere of particle diameter, the microsphere of choosing OK range is as certified products, therefore can cause waste to a certain degree, and the microsphere after the screening distributes and still to allow broad, has a certain proportion of small particle diameter microsphere like this in the finished product.Because the little microsphere surface of particle diameter is long-pending big, the prominent phenomenon of releasing of medicine in the dispose procedure in too high external, the body that causes the long-acting slow-release micro-balloon injection easily of small particle diameter microsphere ratio in the injection.If prominent release excessively, release amount of medicine is excessive, can cause untoward reaction to strengthen.In general, it is little that the medicine that microsphere is sealed is generally dosage, and the medicine of strong drug action is therefore prominently released phenomenon and caused the odd-numbered day dosage too high easily, produces intoxicating phenomenon.In addition, microsphere preparation technology commonly used can not comparatively accurately control the size and the distribution of microsphere in preparation process, this can cause the differences between batches of the size of microspheres product and distribution big, and external, the intravital release of medicine can not be controlled preferably.Therefore, method for preparing microsphere commonly used at present is necessary to reform, thereby is able to evenly control the purpose of microspherulite diameter.
It is more that microsphere prominent released the phenomenon reason, except particle diameter difference is big, the dissolubility that also has medicine self, preparation technology, quality (the molecular weight ranges of encapsulating material, the ratio of oligomer) etc., one of them major reason of ignoring easily is exactly will be according to the characteristics of entrapped drug, note adopting the polylactic acid-based material of suitable end group modification, report as patent (CN1723895A), employing terminal residues such as the flat field of invention population do not have esterification to modify, band carboxyl (PLGA COOH), adopt traditional emulsifying (O/W)-solvent evaporation method, preparation huperzine A microsphere, the result shows, adopting end is the PLGA material of carboxyl, can improve the drug loading and the envelop rate of huperzine A, release in vitro shows simultaneously, but adopting prominent the releasing of the PLGA better controlled microsphere of this kind specification. the PLGA material of not analyzing terminal band carboxyl in this patent can improve drug loading, the prominent reason of releasing of envelop rate and reduction. in fact, these physics and chemistry characteristics with medicine self are relevant. and huperzine A is an alkaloid, basic group in the molecular structure is a primary amine, polarity is big, therefore huperzine A has certain water solublity (0.8mg/ml, 25 ℃), therefore the envelop rate of emulsifying (the O/W)-solvent evaporation method that adopts usually is low, drug loading is low, medicine spreads the microsphere surface that is caused in Emulsion micropore is many, therefore prominent to release phenomenon serious for medicine. when utilizing PLGA to seal to contain the medicine of amine groups, can utilize end not have esterification to modify, band carboxyl (COOH) material, can utilize microsphere Chinese medicine and carrier interactions, be the carboxyl formation hydrogen bond of the amido of medicine with material, thereby can play stable entrapped drug, improve drug loading, envelop rate. the rate of release of microsphere Chinese medicine is also owing to medicine is controlled better with the hydrogen bond action of carrier material. and Shang Shi leuprorelin long-acting release injectable microsphere utilizes amido in the medicine to follow the hydrogen bond action of the carboxyl of material just the earliest, material selection PLGA-COOH (Okada H, One-and three-month release injectable microspheres ofLH-RH superagonist leuporelin acetate[J] .Advanced Drug Delivery Review, 1997,28 (1): 43-47).Galantamine is an alkaloid, in the molecular structure tertiary amine is arranged, and also can utilize this construction features, improves drug loading, envelop rate and the sustained release of microsphere.
The prominent problem of releasing at the huperzine A microsphere, the inventor Chen Qing China of patent (CN1981744A) etc., start with by preparation method, adopt emulsifying (W/O)-solvent evaporation method to prepare microsphere, external release test shows, prominent the releasing preferably of microsphere controlled, but release 1d is released to 16% in the body, and dashing forward, it is still more obvious to release phenomenon.The method of emulsifying (W/O) prepares microsphere, and subsequent treatment comparatively bothers, and generally is of little use.This preparation method foreign minister is a corn wet goods vegetable oil, emulsifying agent is Span80, therefore the cleaning of microsphere needs organic solvents such as petroleum ether, is unfavorable for the large-scale production preparation of microsphere, and the control of residual Span80 emulsifying agent also is a considerable problem in the microsphere.
External long-acting slow-release micro-balloon injection such as the leuprorelin acetate microsphere that has gone on the market, the technology that adopts in the production is stirring and emulsifying (W/O/W)-solvent evaporation method, this kind of domestic imitation also is to adopt this production technology, this production technology is by the mechanical agitation work done, the dichloromethane solution that disperses PLGA forms W/O/W, after the solvent evaporates, emulsion droplet solidifies, and promptly forms microsphere.Though having certain production application, production technology is worth, but adopt this method to prepare microsphere, exist prepared in laboratory and excessively arrive pilot-scale, a production-scale technology amplification difficult problem, reason just is that along with preparative scale increase the emulsifying effectiveness of stirring and emulsifying is not easy control.In addition, size and distribution depends on the prepared emulsion droplet of stirring and emulsifying size and distributes in this production technology, but because the inhomogeneities of mechanical agitation force distribution, cause the emulsion droplet size difference that forms big, so the microspherulite diameter of this prepared size and distribute all wayward.
Prepare the technology amplification difficult problem that microsphere exists at stirring and emulsifying (O/W)-solvent evaporation method, design such as patent inventor marquis's Huimin (CN2719296Y) has prepared special equipment and can utilize this method to prepare the device of microsphere continuously, improved production efficiency, and can continuous production.This equipment can solve emulsifying (O/W)-volatility process microsphere preparation technology's an amplification difficult problem preferably.But this equipment can not carry out size and distribute that to control be bigger sorry microsphere.Another shortcoming is exactly sealing of suitable water-insoluble drug only, is not suitable for water soluble drug and seals the multi-emulsion method of employing (W/O/W)-solvent evaporation method.Vibrating nozzle method (Vibrating nozzle breakup method) can reach the size droplet diameter size that accurate control is produced by nozzle diameter, dither and high-voltage electrostatic field.This method preparation of successfully applying to sodium alginate-polylysine-sodium alginate microcapsule (APA microcapsule) in cell biological engineering field in recent years comes encapsulation of cells and tissue.Have production efficiency height, microcapsule diameter size evenly, the technology advantage that is easy to amplify.External existing laboratory, pilot scale, production-scale microvibrograph are commercially produced equipment (Switzerland Inotech Biosystem company, Inotech Encapsulator series microvibrograph).But Shang Weiyou utilizes this legal system to be equipped with the application report of long-acting release injectable microsphere.Reason is that the purpose of design of microvibrograph is a preparation APA microcapsule, it is more than 300～500 μ m that size requires, and the particle diameter of injectable microsphere is much smaller, about mean diameter 100 μ m, generally be less than 200 μ m, otherwise the syringeability of micro-balloon injection clinical injection administration can be affected.Therefore must design preparation and meet the vibrating nozzle that the injectable microsphere size requires.In addition, what microvibrograph sprayed is sodium alginate aqueous solution, and microsphere preparation is adopted is organic solvent or the W/O colostrums such as dichloromethane of PLGA, and therefore both must carry out big groping and adjusting to technological parameters such as frequency of vibration, voltage of electric field at aspect significant differences such as surface activity, viscositys.
Summary of the invention
At the deficiencies in the prior art, the technical issues that need to address of the present invention are to disclose a kind of novel form of galanthamine long-acting release injectable microsphere composite and new method for preparing microsphere.Employed galantamine (Galanthamine) is a kind of phenanthridine alkaloid that comes from lycoris plants snowflake (Leucojum aestivum) among the present invention, chemistry 11-methyl by name-3-methoxyl group-4 α, 5,9,10,11,12-six hydrogen-6H-benzofuran [3 α, 3,2-ef] [2] benzazepine-6-alcohol.
The inventor furthers investigate at existing technology status, finds by lot of experiment results, adopts following technical proposals to achieve the above object, thereby has finished the present invention.Technical scheme of the present invention is as follows:
A kind of galantamine microsphere comprises galantamine base that accounts for microsphere gross weight 5-40% and the polylactic acid/hydroxy acetate multipolymer that accounts for total microsphere gross weight 60-95%.
Aforesaid galantamine microsphere, optimized technical scheme are that microspherulite diameter is 25-200 μ m, is more preferably 50-150 μ m.Aforesaid galantamine microsphere, optimized technical scheme is, lactic acid (LA) is 30 with the mol ratio of hydroxyacetic acid (GA) in the described polylactic acid/hydroxy acetate multipolymer: 70-70: 30, the molecular weight of described polylactic acid/hydroxy acetate multipolymer is 5000-50000 dalton, is preferably 10000-30000 dalton.Aforesaid galantamine microsphere, optimized technical scheme are that the end group of described polylactic acid/hydroxy acetate multipolymer is-the COOH group.
The present invention also provides a kind of galanthamine long-acting release injectable microsphere composite, and its component and weight percentage are: galantamine microsphere 60-90%, lyophilizing proppant 5-25%, suspending agent 0.5-5%, wetting agent 0.5-5%, osmotic pressure regulator 1-25%.Aforesaid galanthamine long-acting release injectable microsphere composite, preferred scheme be, said lyophilizing proppant is a kind of in mannitol, sucrose, trehalose, the lactose and more than one.Aforesaid galanthamine long-acting release injectable microsphere composite, preferred scheme be, said suspending agent is a kind of in sodium carboxymethyl cellulose, hypromellose, dextran, hetastarch, the polyvinylpyrrolidone and more than one.Aforesaid galanthamine long-acting release injectable microsphere composite, preferably scheme is, and said wetting agent is a Tween 80, and said osmotic pressure regulator is a sodium chloride.
The present invention also provides the preparation method of aforementioned galanthamine long-acting release injectable microsphere composite, comprises following two steps: the preparation of galantamine microsphere and the preparation of lyophilized injectable powder:
The preparation of described galantamine microsphere: adopt the vibrating nozzle method in conjunction with emulsion process (O/W)-solvent evaporation method, step is as follows: galantamine base, polylactic acid/hydroxy acetate multipolymer are dissolved in organic solvent, as decentralized photo; Adopting diameter is 25 or 50 μ m nozzles, frequency of vibration 2000-5000Hz, voltage of electric field 500-1500V, the concentration 0.05-0.5g/ml of polylactic acid/hydroxy acetate multipolymer forms symmetrical liquid drop with decentralized photo in the decentralized photo, be added drop-wise in the polyvinyl alcohol water solution that concentration is 0.1-5wt%, emulsifying is condensed into microsphere, after microsphere solidifies, isolate the galantamine microsphere, washing;
The preparation of described freeze-dried powder: suspending agent, lyophilizing proppant, osmotic pressure regulator, wetting agent are dissolved with sterilized water for injection, antibacterial and the impurity in the reagent is removed in aseptic filtration, suspensoid medium as micro-balloon injection, the galantamine microsphere of preparation is suspended in the suspensoid medium, stir, promptly get the microsphere suspensoid, the settling ratio 15min of suspensoid is greater than 0.8, this suspensoid is sub-packed in the cillin bottle under stirring condition, lyophilization rapidly, moisture is controlled at 0.1-5wt%, promptly gets final finished.
The preparation method of aforementioned galanthamine long-acting release injectable microsphere composite, optimized technical scheme be, is in dichloromethane, ethyl acetate, the acetone one or more at organic solvent described in the preparation of galantamine microsphere.
Main creative contribution of the present invention is embodied in provides a kind of long-acting sustained-release injection based on the galantamine microsphere and preparation method thereof, promptly shows following two aspects:
(1) vibrating nozzle method (Vibrating nozzle breakup method) preparation galantamine microsphere.
This preparation method is that traditional emulsifying (O/W)-solvent evaporation method is innovated, by changing the nozzle of different-diameter size, adjust the factors such as concentration of PLGA in frequency of vibration, voltage of electric field, the decentralized photo, the particle diameter of the decentralized photo when accurately control Emulsion prepares, thereby the emulsion droplet particle diameter that control is produced finally reaches the purpose that the control microspherulite diameter is concentrated relatively.This method have microspherulite diameter size evenly, the clear superiority of narrow distribution range, in addition, it is fast that the vibrating nozzle method generates the speed of drop, the efficient height, the preparation tank capacity carries out the sterile working, production process can be carried out continuously, technology is easy to amplify advantages such as application.The present application people finds that by a large amount of tests this method is specially adapted to the formation of the organic solvent dispersed phase drop of polymeric material.Therefore, the present invention adopts the base of galantamine to prepare microsphere, and does not adopt water miscible hydrobromate.Because be subjected to the restriction of the viscosity factor of decentralized photo, the present application people repeatedly attempts to utilize colostrum (W/O) as decentralized photo, the sustained-release micro-spheres for preparing water soluble drug by multi-emulsion method (W/O/W) does not obtain the comparatively effect of ideal control microspherulite diameter.Therefore, this preparation method is applicable to the preparation of poorly water soluble drugs microsphere.Those skilled in the art understand easily, to some water-soluble organic acid bases medicines, can utilize its base, characteristics that the acidic group water solublity is low, prepare the base of this class medicine or the microsphere of acidic group by vibrating nozzle in conjunction with emulsifying (O/W)-solvent evaporation method.
(2) formation of galanthamine long-acting release injectable microsphere composite.
Above-mentioned galantamine microsphere can be used for preparing galanthamine long-acting release injectable microsphere, be the lyophilized injectable powder of a kind of embedding in cillin bottle, comprising the galantamine microsphere of therapeutic dose and suspending agent, proppant, wetting agent, osmotic pressure regulator, its preferred ingredients and weight percent content comprise: galantamine microsphere 60～90%, lyophilizing proppant 5～25%, suspending agent 0.5～5%, wetting agent 0.5～5%, osmotic pressure regulator 1～25%.Described suspending agent is a sodium carboxymethyl cellulose, hypromellose, polyvinylpyrrolidone.Described proppant is mannitol, sucrose, lactose etc., and it mainly acts on is to play peptizaiton when lyophilization, prevents the adhesion between the microsphere.Described wetting agent is a Tween 80, and it mainly acts on is to make the easy moistening of microsphere surface, thereby microsphere is dispersed in the injection preferably.
Galanthamine long-acting injection sustained-release microspherical composition of the present invention can be used for the syndromic medicine of preparation treatment Alzheimer's, microsphere composition is added sterilized water for injection (addition of water for injection is 1～5 times of galanthamine long-acting injection sustained-release microspherical composition weight), jolting gently, mixing, the intramuscular injection administration.An every two weeks or an injection in month are once.Galantamine in the microsphere discharges by biodegradation, the corrosion of diffusion and PLGA material, and slow-release time can be kept two weeks or one month.
Description of drawings
Fig. 1 is the galantamine PLGA microsphere microphotograph of embodiment 3 preparations.
Fig. 2 is the release in vitro curve of the galantamine PLGA microsphere of embodiment 3 preparations.
Fig. 3 is the release in vitro curve of the galantamine PLGA microsphere of embodiment 7 preparations.
Fig. 4 is the interior release profiles of body of the galantamine PLGA microsphere of embodiment 3 preparations.
Fig. 5 is the interior release profiles of body of the galantamine PLGA microsphere of embodiment 7 preparations.
The specific embodiment
Come technical characterictic of the present invention is described in further detail below in conjunction with specific embodiment.But the present invention is not subjected to the restriction of these specific embodiments.
Raw materials used or equipment all can obtain from market among the embodiment.Wherein, galantamine is available from ChangZhou TianPu Pharmacy Co., Ltd; Polylactic acid/hydroxy acetate multipolymer (PLGA) is available from the Shandong Prov. Medical Apparatus ﹠ Instrument Research Inst; Polyvinyl alcohol 17-88,05-88 is available from Beijing Organic Chemical Plant; Polyvinyl alcohol 1750 is available from chemical reagent purchasing station, Chinese Medicine group Shanghai; Dichloromethane, ethyl acetate, acetone are all available from chemical reagent purchasing station, Chinese Medicine group Jinan; Mannitol is available from Qingdao Mingyue Marine Alga Group Corp., Ltd.; Sucrose is available from Distributions in Liaocheng of Shandong Province peace letter pharmaceutic adjuvant company limited; Trehalose is available from Wuhan Yuancheng Technology Development Co., Ltd.; Sodium carboxymethyl cellulose is available from the mountains and rivers, Huainan, Anhui pharmaceutic adjuvant company limited; Dextran is available from Shanghai Huamao Pharmaceutical Co; Tween 80 is available from Qingdao Tian Liyuan bio tech ltd; Inotech IE50R microvibrograph is available from Switzerland Inotech Biosystem company; Vibrating nozzle ( aperture 25,50 μ m) is available from Switzerland Inotech Biosystem company; Vacuum pump (Xiamen Jim Maclaren Science and Technology Ltd.); The water bath with thermostatic control agitator is available from the suitable magnificent Instr Ltd. in Jintan City; Bag filter (the molecular retention quality is 8000-14400u) is available from Beijing Xia Si biotech company.
The vibrating nozzle method prepares the preparation of microsphere in conjunction with emulsifying (O/W)-solvent evaporation method:
(1) the vibrating nozzle method prepares the technical study of microsphere in conjunction with emulsifying (O/W)-solvent evaporation method: the technological factors such as voltage of concentration, frequency of vibration, electric field of mainly investigating PLGA in the pore size, decentralized photo of vibrating nozzle are to the influence of rounding property, size and distribution, drug loading and the envelop rate of microsphere preparation.(2) prescription research: (LA: GA=50: 50,75: 25) factor such as ratio is to the influence of microsphere drug loading, envelop rate, external release mainly to investigate the ratio, PLGA polymerization single polymerization monomer of medicine and carrier PLGA.
With Inotech IE50R microvibrograph prototype (available from Switzerland Inotech Biosystem company) is the vibrating nozzle method prepares microsphere in conjunction with emulsifying (O/W)-solvent evaporation method microsphere instrument technology platform.Prepare the requirement of microsphere according to instrument own characteristic and emulsifying (O/W)-solvent evaporation method, this instrument has been done following improvement: the critical component of (1) control size is the diameter of vibrating nozzle, and the original nozzle fittings of manufacturer, diameter is respectively 100,150,200,300 μ m do not have the following vibrating nozzle of 100 μ m.Existing vibrating nozzle diameter is excessive, therefore must change the vibrating nozzle of existing instrument.The present application people is by getting in touch with producer, and producer agrees to provide diameter to be respectively the vibrating nozzle of two kinds of diameter specifications of 25,50 μ m according to original jet size size.(2) adopt vacuum pump to bleed, promote the volatilization of organic solvent in the microsphere.
By above measure, Inotech IE50R microvibrograph is improved to the equipment that can be used for the microsphere preparation, inventor's called after: vibrating nozzle method microsphere instrument.Utilize vibrating nozzle method of the present invention successfully to prepare galantamine PLGA microsphere.Technological parameter control is as follows: vibrating nozzle diameter 25 or 50 μ m, the theoretical drug loading 5～50% (percentage by weight) of galantamine, the concentration 5～50% (concentration expressed in percentage by weight) of PLGA in the decentralized photo, frequency of vibration 2000～5000Hz, voltage of electric field 500～1500V can prepare the galantamine PLGA microsphere of size 25～200 μ m.
Embodiment 1: the vibrating nozzle legal system is equipped with galantamine PLGA microsphere.
The about 55mg of precision weighing galantamine base, the about 1000mg of PLGA (monomer ratio LA: GA 50: 50, molecular weight 12000) adds in the 5ml dichloromethane, vortex makes its dissolving fully, make decentralized photo. decentralized photo is transferred in the 20ml glass syringe. adopt the vibrating nozzle method to prepare microsphere in conjunction with emulsion process (O/W)-solvent evaporation method. apparatus for preparation adopts improved vibrating nozzle method microsphere instrument, technological parameter is as follows: the aperture 50 μ m of nozzle, frequency of vibration 2000Hz, voltage of electric field: 500V, the flow velocity 1ml/min of decentralized photo liquid, nozzle can be produced evenly, successive drop splashes in the continuous phase of getting 5%PVA17-88 aqueous solution 200ml, middling speed magnetic agitation 1h, low speed magnetic agitation 4h then, decompression promotes organic solvent performance, centrifugal collection microsphere, washing, vacuum drying is promptly.
Embodiment 2: the vibrating nozzle legal system is equipped with galantamine PLGA microsphere.
The about 130mg of precision weighing galantamine base, the about 1000mg of PLGA (monomer ratio LA: GA 50: 50, molecular weight 12000) adds in the 20ml ethyl acetate, and vortex makes its dissolving fully, makes decentralized photo.Decentralized photo is transferred in the 20ml glass syringe.Adopt the vibrating nozzle method to prepare microsphere in conjunction with emulsion process (O/W)-solvent evaporation method.The system apparatus for preparation adopts improved vibrating nozzle method microsphere instrument, technological parameter is as follows: the aperture 25 μ m of nozzle, frequency of vibration 3000Hz, voltage of electric field: 1000V, the flow velocity 2ml/min of decentralized photo liquid, make nozzle can produce even, successive drop, splash in the continuous phase of getting 2%PVA17-50 aqueous solution 200ml, middling speed magnetic agitation 1h, low speed magnetic agitation 4h then, decompression promotes the organic solvent performance, centrifugal collection microsphere, and washing, vacuum drying are promptly.
Embodiment 3: the vibrating nozzle legal system is equipped with galantamine PLGA microsphere.
The about 300mg of precision weighing galantamine base, the about 1000mg of PLGA (monomer ratio LA: GA 50: 50, molecular weight 12000) adds in the 10ml dichloromethane, and vortex makes its dissolving fully, makes decentralized photo.Decentralized photo is transferred in the 20ml glass syringe.Adopt the vibrating nozzle method to prepare microsphere in conjunction with emulsion process (O/W)-solvent evaporation method.Technological parameter is as follows: the aperture 50 μ m of nozzle, frequency of vibration 2000Hz, voltage of electric field: 1500V, the flow velocity 1ml/min of decentralized photo liquid makes nozzle can produce even, successive drop, splash in the continuous phase of getting 1.0%PVA17-88 aqueous solution 200ml, middling speed magnetic agitation 1h, low speed magnetic agitation 4h then, decompression promotes the organic solvent performance, centrifugal collection microsphere, washing, vacuum drying are promptly.
The microscopic examination photo of the microsphere of embodiment 3 preparations is seen Figure of description 1, as seen from the figure, adopts vibrating nozzle legal system of the present invention to be equipped with the galantamine microsphere, can effectively control the microspherulite diameter size, distributes and concentrates, and microspherulite diameter concentrates on 75～150 μ m.
Embodiment 4: the vibrating nozzle legal system is equipped with galantamine PLGA microsphere.
The about 550mg of precision weighing galantamine base, the about 1000mg of PLGA (monomer ratio LA: GA 50: 50, molecular weight 12000) adds in the 5ml acetone, and vortex makes its dissolving fully, makes decentralized photo.Decentralized photo is transferred in the 20ml glass syringe.Adopt the vibrating nozzle method to prepare microsphere in conjunction with emulsion process (O/W)-solvent evaporation method, technological parameter is as follows: the aperture 25 μ m of nozzle, frequency of vibration 3000Hz, voltage of electric field: 500V, the flow velocity 1ml/min of decentralized photo liquid, make nozzle can produce even, successive drop, splash in the continuous phase of getting 0.5%PVA17-88 aqueous solution 200ml, middling speed magnetic agitation 1h, low speed magnetic agitation 4h then, decompression promotes the organic solvent performance, centrifugal collection microsphere, and washing, vacuum drying are promptly.
Embodiment 5: the vibrating nozzle legal system is equipped with galantamine PLGA microsphere.
The about 750mg of precision weighing galantamine base, the about 1000mg of PLGA (monomer ratio LA: GA 50: 50, molecular weight 12000) adds in the 10ml ethyl acetate, and vortex makes its dissolving fully, makes decentralized photo.Decentralized photo is transferred in the 20ml glass syringe.Adopt the vibrating nozzle method to prepare microsphere in conjunction with emulsion process (O/W)-solvent evaporation method, technological parameter is as follows: the aperture 50 μ m of nozzle, frequency of vibration 5000Hz, voltage of electric field: 1000V, the flow velocity 1ml/min of decentralized photo liquid, make nozzle can produce even, successive drop, splash in the continuous phase of getting 0.5%PVA17-88 aqueous solution 200ml, middling speed magnetic agitation 1h, low speed magnetic agitation 4h then, decompression promotes the organic solvent performance, centrifugal collection microsphere, and washing, vacuum drying are promptly.
Embodiment 6: the vibrating nozzle legal system is equipped with galantamine PLGA microsphere.
Precision weighing galantamine base 130 about mg, the about 1000mg of PLGA (monomer ratio LA: GA 75: 25, molecular weight 15000) adds to 2ml organic solvent (dichloromethane 1ml, acetone is 1ml) in, vortex makes its dissolving fully, make decentralized photo. decentralized photo is transferred in the 20ml glass syringe. adopt the vibrating nozzle method to prepare microsphere in conjunction with emulsion process (O/W)-solvent evaporation method, technological parameter is as follows: the aperture 50 μ m of nozzle, frequency of vibration 3000Hz, voltage of electric field: 1000V, the flow velocity 0.5ml/min of decentralized photo liquid can produce evenly nozzle, successive drop, splash in the continuous phase of getting 5%PVA17-88 aqueous solution 300ml, middling speed magnetic agitation 1h, low speed magnetic agitation 4h then, decompression promotes the organic solvent performance, centrifugal collection microsphere, washing, be drying to obtain.
Embodiment 7: the vibrating nozzle legal system is equipped with galantamine PLGA microsphere.
Precision weighing galantamine base 300 about mg, the about 1000mg of PLGA (monomer ratio LA: GA 75: 25, molecular weight 15000) adds in the 10ml dichloromethane, and vortex makes its dissolving fully, makes decentralized photo.Decentralized photo is transferred in the 20ml glass syringe.Adopt the vibrating nozzle method to prepare microsphere in conjunction with emulsion process (O/W)-solvent evaporation method, technological parameter is as follows: the aperture 50 μ m of nozzle, frequency of vibration 3000Hz, voltage of electric field: 1500V, the flow velocity 1ml/min of decentralized photo liquid, make nozzle can produce even, successive drop, splash in the continuous phase of getting 1%PVA05-88 aqueous solution 300ml, middling speed magnetic agitation 1h, low speed magnetic agitation 4h then, decompression promotes the organic solvent performance, and centrifugal collection microsphere is washed, is drying to obtain.
Embodiment 8: the vibrating nozzle legal system is equipped with galantamine PLGA microsphere.
Precision weighing galantamine base 550 about mg, and the about 1000mg of PLGA (monomer ratio LA: GA75: 25, molecular weight 15000) add in the 5ml dichloromethane, vortex makes its dissolving fully, makes decentralized photo.Decentralized photo is transferred in the 20ml glass syringe.Adopt the vibrating nozzle method to prepare microsphere in conjunction with emulsion process (O/W)-solvent evaporation method, technological parameter is as follows: the aperture 25 μ m of nozzle, frequency of vibration 2000Hz, voltage of electric field: 500V, the flow velocity 1ml/min of decentralized photo liquid, make nozzle can produce even, successive drop, splash in the continuous phase of getting 2%PVA17-88 aqueous solution 300ml, middling speed magnetic agitation 1h, low speed magnetic agitation 4h then, decompression promotes the organic solvent performance, and centrifugal collection microsphere is washed, is drying to obtain.
Embodiment 9: the preparation of galanthamine long-acting release micro-balloon injection (slow release cycle two weeks).
Prescription is formed: (with 100 radiacmeters)
Galantamine base 15g
PLGA (monomer ratio LA: GA 50: 50, molecular weight 12000) 50g
Mannitol 20g sodium carboxymethyl cellulose 1.5g
Sodium chloride 1.5g Tween 80 0.5g
Preparation technology: prepare microsphere according to embodiment 3 described methods.Mannitol, sodium carboxymethyl cellulose, sodium chloride and Tween 80 are dissolved with sterilized water for injection, and antibacterial and the impurity in the reagent is removed in 0.22 μ m microporous filter membrane aseptic filtration, as the suspensoid substrate of micro-balloon injection.Microsphere is suspended in the suspensoid substrate, stirs, promptly get the microsphere suspensoid.This suspensoid is sub-packed under stirring condition in the 10ml cillin bottle, simultaneously freezing rapidly, the sample that freezes is placed freezer dryer, add the lyophilizing plug, lyophilization 72h, moisture meets the requirements, and the aluminium lid sealing promptly gets final finished.
Embodiment 10: the preparation of galanthamine long-acting release micro-balloon injection (slow release cycle two weeks).
Prescription is formed: (with 100 radiacmeters)
Galantamine base 15g
PLGA (monomer ratio LA: GA 50: 50, molecular weight 12000) 50g
Trehalose 25g sodium carboxymethyl cellulose 1.5g
Sodium chloride 2g Tween 80 0.5g
Preparation technology: prepare microsphere according to embodiment 3 described methods. with mannitol, sodium carboxymethyl cellulose, sodium chloride and Tween 80 dissolve with sterilized water for injection, 0.22 antibacterial and impurity in the reagent are removed in the aseptic filtration of μ m microporous filter membrane, suspensoid substrate as micro-balloon injection. microsphere is suspended in the suspensoid substrate, stir, promptly get the microsphere suspensoid. under stirring condition, be sub-packed in this suspensoid in the 10ml cillin bottle, simultaneously freezing rapidly, the sample that freezes is placed freezer dryer, add the lyophilizing plug, lyophilization 72h, moisture meets the requirements, and the aluminium lid sealing promptly gets final finished.
Embodiment 11: the preparation of galanthamine long-acting release micro-balloon injection (slow release cycle two weeks).
Prescription is formed: (with 100 radiacmeters)
Galantamine base 15g
PLGA (monomer ratio LA: GA 50: 50, molecular weight 12000) 50g
Sucrose 40g sodium carboxymethyl cellulose 5g
Sodium chloride 1.5g Tween 80 1.5g
Preparation technology: prepare microsphere according to embodiment 3 described methods.Mannitol, sodium carboxymethyl cellulose, sodium chloride and Tween 80 are dissolved with sterilized water for injection, and antibacterial and the impurity in the reagent is removed in 0.22 μ m microporous filter membrane aseptic filtration, as the suspensoid substrate of micro-balloon injection.Microsphere is suspended in the suspensoid substrate, stirs, promptly get the microsphere suspensoid.This suspensoid is sub-packed under stirring condition in the 10ml cillin bottle, simultaneously freezing rapidly, the sample that freezes is placed freezer dryer, add the lyophilizing plug, lyophilization 72h, moisture meets the requirements, and the aluminium lid sealing promptly gets final finished.
Embodiment 12: the preparation of galanthamine long-acting release micro-balloon injection (1 month slow release cycle).
Prescription is formed: (with 100 radiacmeters)
Galantamine base 15g
PLGA (monomer ratio LA: GA 75: 25, molecular weight 15000) 50g
Mannitol 20g dextran 1 .5g
Sodium chloride 1.5g Tween 80 0.5g
Make each technology: prepare microsphere according to embodiment 7 described methods.Mannitol, sodium carboxymethyl cellulose, sodium chloride and Tween 80 are dissolved with sterilized water for injection, and antibacterial and the impurity in the reagent is removed in 0.22 μ m microporous filter membrane aseptic filtration, as the suspensoid substrate of micro-balloon injection.Microsphere is suspended in the suspensoid substrate, stirs, promptly get the microsphere suspensoid.This suspensoid is sub-packed under stirring condition in the 10ml cillin bottle, simultaneously freezing rapidly, the sample that freezes is placed freezer dryer, add the lyophilizing plug, lyophilization 72h, moisture meets the requirements, and the aluminium lid sealing promptly gets final finished.
Embodiment 13: the preparation of galanthamine long-acting release micro-balloon injection (1 month slow release cycle).
Prescription is formed: (with 100 radiacmeters)
Galantamine base 15g
PLGA (monomer ratio LA: GA 75: 25, molecular weight 15000) 50g
Sucrose 25g sodium carboxymethyl cellulose 1.5g
Sodium chloride 1.5g Tween 80 0.5g
Preparation technology: prepare microsphere according to embodiment 7 described methods.Mannitol, sodium carboxymethyl cellulose, sodium chloride and Tween 80 are dissolved with sterilized water for injection, and antibacterial and the impurity in the reagent is removed in 0.22 μ m microporous filter membrane aseptic filtration, as the suspensoid substrate of micro-balloon injection.Microsphere is suspended in the suspensoid substrate, stirs, promptly get the microsphere suspensoid.This suspensoid is sub-packed under stirring condition in the 10ml cillin bottle, simultaneously freezing rapidly, the sample that freezes is placed freezer dryer, add the lyophilizing plug, lyophilization 72h, moisture meets the requirements, and the aluminium lid sealing promptly gets final finished.
Experimental example 1:HPLC-UV method is measured the drug loading and the envelop rate of galantamine microsphere.
Chromatographic condition: Shimpack ODS C
18Post (150mm * 5mm, 5 μ m); Mobile phase: methanol-water-glacial acetic acid (75: 925: 10); UV detects wavelength: 289nm; Flow velocity: 1.0ml/min; Sample size: 20 μ l.Under this chromatographic condition, the galantamine retention time is 6.7min, and number of theoretical plate is calculated as 1800 by the galantamine peak.
Content assaying method: precision takes by weighing galantamine microsphere an amount of (containing galantamine 5mg approximately) and puts in the 10ml measuring bottle, add acetonitrile 2ml, vortex is to dissolving, use methanol constant volume, shake up. filter with 0.22 μ m nylon leaching film, get subsequent filtrate with 10 times of mobile phase dilutions, centrifugal (behind 17000 * g) 10min, get supernatant 20 μ l sample introductions, the HPLC method is measured content. the calculating of drug loading and envelop rate:
Drug loading (%)=(contained drug quality in the microsphere)/(gross mass of microsphere) * 100%
Envelop rate (%)=(the actual drug loading of microsphere)/(the theoretical drug loading of microsphere) * 100%
The drug loading and the entrapment efficiency determination of experimental result and discussion: embodiment 1～8 microsphere the results are shown in Table 1.Can find that by table 1 the PLGA material of two kinds of different monomers ratios does not have significant difference to drug loading, the envelop rate of galantamine.Along with the rising of theoretical drug loading, the envelop rate of microsphere reduces gradually, is reduced to 68.1% by the highest 93.2%.Theoretical medicine carrying dose is 23% o'clock, and envelop rate still can keep higher level, 86.7%, meet pharmacopeia to the envelop rate requirement in the microparticle formulation guideline.
The drug loading and the entrapment efficiency determination of table 1 galanthamine long-acting release microsphere
| Sample | PLGA (LA: GA) monomer ratio | Theoretical drug loading (%) | Actual drug loading (%) | Envelop rate (%) |
| Embodiment 1 | ??50∶50 | ??5.40 | ??5.03 | ??93.2 |
| |
??50∶50 | ??11.49 | ??10.05 | ??87.5 |
| Embodiment 3 | ??50∶50 | ??23.13 | ??20.05 | ??86.7 |
| |
??50∶50 | ??34.71 | ??26.52 | ??76.4 |
| |
??50∶50 | ??42.63 | ??29.11 | ??68.3 |
| |
??75∶25 | ??11.79 | ??10.39 | ??88.1 |
| Embodiment 7 | ??75∶25 | ??23.19 | ??19.92 | ??85.9 |
| |
??75∶25 | ??35.32 | ??26.38 | ??74.7 |
Experimental example 2: the outer release test of the microsphere of galantamine microsphere.
Experimental technique: precision takes by weighing galantamine microsphere an amount of (containing galantamine 10mg approximately), put in the bag filter, add 0.01mol/L physiology isotonic phosphate buffer liquid (pH7.4, contain 0.02%NaN3,0.1% Tween 80) 0.5ml is with dispersion microsphere, then bag filter is put among 0.01mol/L physiology isotonic phosphate buffer liquid (pH7.4) 50ml, in 37 ℃ of constant temperature shaking tables, 50 times/min, jolting is regularly changed whole media apart from 4cm/ time, discharges liquid through 0.22 μ m filtering with microporous membrane, get subsequent filtrate 20 μ l sample introductions and measure, the HPLC-UV method is measured dissolution medium Chinese medicine content.
The external release curve of experimental result and discussion: embodiment 3 described microspheres is seen Figure of description 2, and as seen from the figure, the microsphere release in vitro of embodiment 3 is comparatively constant, 1d discharges 10.1%, the not prominent phenomenon of releasing, and 7d discharges 52.3%, 14d discharges 92.1%, and the sustainable release of microsphere reaches 14d.The release curve is seen accompanying drawing 3 in the body of embodiment 7 described microspheres, and as seen from the figure, the microsphere release in vitro of embodiment 7 is comparatively constant, and 1d discharges 8.3%, the not prominent phenomenon of releasing, and 14d discharges 45.1%, and 28d discharges 89.6%, and the sustainable release of microsphere reaches 30d.
Experimental example 3: release test in the microsphere of galantamine microsphere.
Test objective: investigate said preparation release performance in animal body.
Test specimen: according to the galanthamine long-acting release microsphere of the embodiment of the invention 3 and 7 described method preparations.
Experimental animal: the SD rat, 36, male and female half and half are divided into 6 groups at random, 6 every group.
Test method: it is subcutaneous that the galantamine microsphere is injected rat abdomen, carefully cuts the microsphere and the muscular tissue of injection site in different intervals, measures residual dose behind the homogenization, reflects drug release rate in the body of microsphere indirectly.Precision takes by weighing microsphere and puts in right amount in the ampoule, with the sterilized water for injection solution suspendible that contains 0.5% carmethose and 0.1% Tween 80.Every rat is in abdominal part hypodermic 0.5ml (being equivalent to 12mg).With remaining microsphere in an amount of acetonitrile dissolving syringe and the ampoule, measure remaining dose simultaneously, calculate actual dosage.
Sampling method and time point: rat is steam again and raises, respectively at d1 behind the injectable microsphere, 3,5,7,10,14 (embodiment 3 described microspheres), d1,7,14,21,35 (embodiment 7 said microspheres) are put to death 1 group, cut the epidermis of injection site open, carefully take off microsphere and surrounding tissue, thinly slice after freezing, put in the glass homogenizer, add acetonitrile-water (9: 1) 2ml, grind 5min repeatedly, be diluted to 10ml with mobile phase, the vortex mixing, centrifugally (behind 17000 * g) 10min, get supernatant 50 μ l sample introductions, the content of galantamine in the HPLC-UV method working sample.
The release curve is seen Figure of description 4 in the body of experimental result and discussion: embodiment 3 described microspheres.As seen from the figure, discharge in the body of embodiment 3 described microspheres comparatively constantly, 1d discharges 12.1%, and 7d discharges 58.3%, and 14d discharges 94.7% and almost released whole medicines with the drug release rate of every day 6.6%.This release pattern and the cycle galantamine slow releasing injection as the slow release two weeks is more rational.The release curve is seen Figure of description 5 in the body of embodiment 7 described microspheres.As seen from the figure, the interior release of the body of embodiment 7 described microspheres is comparatively constant, and 1d discharges 10.4%, does not significantly dash forward and releases phenomenon.14d discharges 52.1%, and 28d discharges 86.1%.Drug release rate with every day 3.1% has almost been released whole medicines.This release pattern and cycle are more rational as one month injection of galantamine slow release.
Experimental example 4: galanthamine long-acting release injectable microsphere pharmacodynamic experiment.
Experiment purpose: rat memory acquisition disturbance modelling verification galanthamine long-acting release injectable microsphere improves the learning and memory effect to rat due to the employing scopolamine.
Laboratory animal: 40 of SD rats, male and female are not limit.
Medicine and instrument: scopolamine hydrobromide injection (Shanghai Hefeng Pharmaceutical Co., Ltd., specification: 0.3mg:1ml); Galanthamine hydrobromide injection (Shanghai Xudong Hipu Medicine Co., Ltd, specification: 1mg:1ml); Galanthamine long-acting release micro-balloon injection (embodiment 3, the actual drug loading 20.05% of microsphere).
Experimental technique:
The foundation of Morris water maze method: adopt literature method (Duan Xin, Ma Guangyu. naloxone and galantamine are to the intervention effect [J] of rat space working memory obstacle due to the scopolamine. Chinese clinical rehabilitation, 2005; 9 (16): the 110-111. section is new, Ma Guangyu. and naloxone improves the neuromechanism research [J] of rat space working memory obstacle due to the scopolamine. mental sickness and mental health, 2004; 4 (6): 413-413.).By training every rat performance to present stable.
Medication: the SD rat is divided into normal control group, scopolamine group, galantamine injection group treatment group, galanthamine long-acting release injectable microsphere treatment group at random.Every group 10.
Dosage and route of administration: scopolamine is pressed 0.4mg/kg, intraperitoneal injection, and be administered once every day, successive administration 14 days; The galantamine injection is pressed 2mg/kg, intraperitoneal injection, and be administered once every day, successive administration 14 days; The normal control group gives the equal-volume normal saline, and be administered once every day, successive administration 14 days; Galanthamine long-acting release injectable microsphere is pressed 28mg/kg, the smart microsphere that claims, and the suspensoid suspendible, the abdominal part hypodermic administration is in 0d administration 1 time.
Experimental record and MAIN OUTCOME MEASURES: in 1d, 7d, 14d, 16d, the escape latency of every rat is write down in the operation of beginning water maze delay coupling after the 20d administration, and data t inspection statistics is analyzed.
Experimental result: the result shows, to in by the rat memory acquisition disturbance model test due to the scopolamine, the galanthamine long-acting release micro-balloon injection has significant curative effect to rat memory acquisition disturbance model, efficacy strength and conventional galantamine injection (same dose, be administered once every day) are suitable.Galanthamine long-acting release micro-balloon injection administration 1d is a produce effects, and this effect can be maintained until 16d, and the 20d effect disappears.Results of pharmacodynamic test shows that the galanthamine long-acting release injectable agent has tangible medicament slow release, drug effect long-acting.
Claims (10)
1. a galantamine microsphere is characterized in that, comprises galantamine base that accounts for microsphere gross weight 5-40% and the polylactic acid/hydroxy acetate multipolymer that accounts for total microsphere gross weight 60-95%.
2. galantamine microsphere according to claim 1 is characterized in that, microspherulite diameter is 25-200 μ m, is preferably 50-150 μ m.
3. galantamine microsphere according to claim 1, it is characterized in that, lactic acid (LA) is 30 with the mol ratio of hydroxyacetic acid (GA) in the described polylactic acid/hydroxy acetate multipolymer: 70-70: 30, the molecular weight of described polylactic acid/hydroxy acetate multipolymer is 5000-50000 dalton, is preferably 10000-30000 dalton.
4. galantamine microsphere according to claim 3 is characterized in that, the end group of described polylactic acid/hydroxy acetate multipolymer is-the COOH group.
5. a galanthamine long-acting release injectable microsphere composite is characterized in that, component and weight percentage are: galantamine microsphere 60-90%, lyophilizing proppant 5-25%, suspending agent 0.5-5%, wetting agent 0.5-5%, osmotic pressure regulator 1-25%.
6. galanthamine long-acting release injectable microsphere composite according to claim 5 is characterized in that, said lyophilizing proppant is a kind of in mannitol, sucrose, trehalose, the lactose and more than one.
7. galanthamine long-acting release injectable microsphere composite according to claim 5, it is characterized in that said suspending agent is a kind of in sodium carboxymethyl cellulose, hypromellose, dextran, hetastarch, the polyvinylpyrrolidone and more than one.
8. galanthamine long-acting release injectable microsphere composite according to claim 5 is characterized in that, said wetting agent is a Tween 80, and said osmotic pressure regulator is a sodium chloride.
9. the preparation method of the arbitrary described galanthamine long-acting release injectable microsphere composite of claim 5-8 is characterized in that, comprises following two steps: the preparation of galantamine microsphere and the preparation of lyophilized injectable powder:
The preparation of described galantamine microsphere: adopt the vibrating nozzle method in conjunction with emulsion process (O/W)-solvent evaporation method, step is as follows: galantamine base, polylactic acid/hydroxy acetate multipolymer are dissolved in organic solvent, as decentralized photo; Adopting diameter is 25 or 50 μ m nozzles, frequency of vibration 2000-5000Hz, voltage of electric field 500-1500V, the concentration 0.05-0.5g/ml of polylactic acid/hydroxy acetate multipolymer forms symmetrical liquid drop with decentralized photo in the decentralized photo, be added drop-wise in the polyvinyl alcohol water solution that concentration is 0.1-5wt%, emulsifying is condensed into microsphere, after microsphere solidifies, isolate the galantamine microsphere, washing;
The preparation of described freeze-dried powder: suspending agent, lyophilizing proppant, osmotic pressure regulator, wetting agent are dissolved with sterilized water for injection, antibacterial and the impurity in the reagent is removed in aseptic filtration, suspensoid medium as micro-balloon injection, the galantamine microsphere of preparation is suspended in the suspensoid medium, stir, promptly get the microsphere suspensoid, the settling ratio 15min of suspensoid is greater than 0.8, this suspensoid is sub-packed in the cillin bottle under stirring condition, lyophilization rapidly, moisture is controlled at 0.1-5wt%, promptly gets final finished.
10. the preparation method of the described galanthamine long-acting release injectable microsphere composite of claim 9 is characterized in that, is in dichloromethane, ethyl acetate, the acetone one or more at organic solvent described in the preparation of galantamine microsphere.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102302927A CN101703482B (en) | 2009-11-20 | 2009-11-20 | Galanthamine long-acting release injectable microsphere composite and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102302927A CN101703482B (en) | 2009-11-20 | 2009-11-20 | Galanthamine long-acting release injectable microsphere composite and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101703482A true CN101703482A (en) | 2010-05-12 |
| CN101703482B CN101703482B (en) | 2012-01-04 |
Family
ID=42373779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102302927A Active CN101703482B (en) | 2009-11-20 | 2009-11-20 | Galanthamine long-acting release injectable microsphere composite and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101703482B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102423300A (en) * | 2011-11-24 | 2012-04-25 | 河北科技大学 | Acetyl amino abamectin sustained-release microsphere and preparation method as well as sustained-release microsphere injection |
| CN103622971A (en) * | 2013-12-16 | 2014-03-12 | 中国药科大学 | Medicament composition for preventing and/or treating alzheimer diseases and application thereof |
| CN107320770A (en) * | 2017-07-12 | 2017-11-07 | 江苏西宏生物医药有限公司 | One kind injection implant |
| CN108096212A (en) * | 2017-12-25 | 2018-06-01 | 河北科技大学 | Preparation method of drug microspheres with hydroxyethyl starch 200/0.5 as carrier |
| CN111643483A (en) * | 2020-07-06 | 2020-09-11 | 济南大学 | Novel method for preparing galanthamine sustained-release microspheres |
| CN111728957A (en) * | 2020-07-06 | 2020-10-02 | 济南大学 | Tolterodine long-acting sustained-release microsphere and preparation method thereof |
| CN112823792A (en) * | 2019-11-20 | 2021-05-21 | 鲁南制药集团股份有限公司 | Galanthamine pamoate sustained-release microspheres for injection and preparation method thereof |
| CN113384536A (en) * | 2020-03-14 | 2021-09-14 | 鲁南制药集团股份有限公司 | Galanthamine pamoate sustained-release particles for injection and preparation method thereof |
| CN113440597A (en) * | 2021-07-02 | 2021-09-28 | 山东谷雨春生物科技有限公司 | Method for preparing leuprorelin microspheres |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200069696A1 (en) * | 2018-08-30 | 2020-03-05 | Yunxiang Liu | Ophthalmic injectable formulation preparing and oculopathy treating and preventing |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101269045A (en) * | 2008-05-16 | 2008-09-24 | 北京正大绿洲医药科技有限公司 | Galantamin hydrobromide sustained-release dropping pill and preparation method thereof |
-
2009
- 2009-11-20 CN CN2009102302927A patent/CN101703482B/en active Active
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102423300A (en) * | 2011-11-24 | 2012-04-25 | 河北科技大学 | Acetyl amino abamectin sustained-release microsphere and preparation method as well as sustained-release microsphere injection |
| CN103622971A (en) * | 2013-12-16 | 2014-03-12 | 中国药科大学 | Medicament composition for preventing and/or treating alzheimer diseases and application thereof |
| CN103622971B (en) * | 2013-12-16 | 2016-02-17 | 中国药科大学 | A kind of medical composition and its use being used for the treatment of and/or preventing Alzheimer |
| CN107320770A (en) * | 2017-07-12 | 2017-11-07 | 江苏西宏生物医药有限公司 | One kind injection implant |
| CN108096212A (en) * | 2017-12-25 | 2018-06-01 | 河北科技大学 | Preparation method of drug microspheres with hydroxyethyl starch 200/0.5 as carrier |
| CN108096212B (en) * | 2017-12-25 | 2020-06-09 | 河北科技大学 | Preparation method of drug microspheres with hydroxyethyl starch 200/0.5 as carrier |
| CN112823792A (en) * | 2019-11-20 | 2021-05-21 | 鲁南制药集团股份有限公司 | Galanthamine pamoate sustained-release microspheres for injection and preparation method thereof |
| CN112823792B (en) * | 2019-11-20 | 2023-07-14 | 鲁南制药集团股份有限公司 | Sustained release microsphere of galanthamine pamoate for injection and preparation method thereof |
| CN113384536A (en) * | 2020-03-14 | 2021-09-14 | 鲁南制药集团股份有限公司 | Galanthamine pamoate sustained-release particles for injection and preparation method thereof |
| WO2021184610A1 (en) * | 2020-03-14 | 2021-09-23 | 山东新时代药业有限公司 | Galantamine pamoate sustained-release microparticles for injection, and preparation method therefor |
| CN113384536B (en) * | 2020-03-14 | 2024-04-02 | 鲁南制药集团股份有限公司 | Sustained release galanthamine pamoate particles for injection and preparation method thereof |
| CN111728957A (en) * | 2020-07-06 | 2020-10-02 | 济南大学 | Tolterodine long-acting sustained-release microsphere and preparation method thereof |
| CN111643483A (en) * | 2020-07-06 | 2020-09-11 | 济南大学 | Novel method for preparing galanthamine sustained-release microspheres |
| CN113440597A (en) * | 2021-07-02 | 2021-09-28 | 山东谷雨春生物科技有限公司 | Method for preparing leuprorelin microspheres |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101703482B (en) | 2012-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101703482B (en) | Galanthamine long-acting release injectable microsphere composite and preparation method thereof | |
| Zhang et al. | Nano-in-micro alginate/chitosan hydrogel via electrospray technology for orally curcumin delivery to effectively alleviate ulcerative colitis | |
| CN102740895A (en) | Nanoconjugates and nanoconjugate formulations | |
| Fang et al. | Characterizing the release mechanism of donepezil-loaded PLGA microspheres in vitro and in vivo | |
| CN103239730A (en) | Medical sodium alginate gel microsphere and preparation method and application thereof | |
| Guo et al. | High oral bioavailability of 2-methoxyestradiol in PEG-PLGA micelles-microspheres for cancer therapy | |
| CN101984958A (en) | Nanoscale albendazole micropowder and preparation method thereof | |
| CN114917362B (en) | Lipid nanoparticle and preparation method and application thereof | |
| CN106361724B (en) | A sustained release nanometer microsphere composition of 20(R) -ginsenoside Rg3 and its preparation method | |
| CN103585113A (en) | Apigenin polylactic acid sustained release microsphere and preparation method thereof | |
| CN101955505A (en) | Novel immune suppressor and composition thereof | |
| Wang et al. | Reduced burst release and enhanced Oral bioavailability in Shikimic acid–loaded Polylactic acid submicron particles by coaxial electrospray | |
| CN102525936B (en) | Compound epirubicin hydrochloride polylactic-co-glycolic acid (PLGA) nanoparticles and preparation method thereof | |
| CN110251487B (en) | Preparation method and application of alcohol soluble protein nanoparticles for improving drug-loading rate and oral bioavailability of docetaxel | |
| CN102048702B (en) | Bifendate nano crystal preparation and preparation method thereof | |
| JP2002538195A (en) | Delivery of microparticulate formulations using needle-free injectors for sustained release of bioactive compounds | |
| CN103520119B (en) | The preparation method of imidocard dipropionate long-acting veterinary preparation | |
| CN102552216B (en) | Snake poison pain-relieving polypeptide nanocapsule and preparation method and application thereof | |
| CN101810586B (en) | L-dopa methyl ester sustained-release microsphere composite and preparation method thereof | |
| CN104546741A (en) | Preparation method and application of 2-methoxyestradiol albumin nano freeze-dried agent | |
| CN108498455A (en) | A kind of water-soluble medicament nano crystalline substance of oiliness and preparation method thereof | |
| CN103040791A (en) | Asiatic acid lipid nanoparticle capable of stimulating oral absorption and preparation method thereof | |
| Kawashima | Spherical crystallization as a new platform for particle design engineering | |
| CN101884622B (en) | Benserazide sustained-release microspherical composition and preparation method thereof | |
| Srikar et al. | Study On Influence Of Process Parameters On Quality Of Lovastatin Microspheres By Design Of Experiments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170309 Address after: 273400 Shandong province Feixian County North Ring Road No. 1 Patentee after: Shandong Xinshidai Pharmaceutical Industry Co., Ltd. Address before: Ji'nan City Central Jiwei Road No. 106 250022 Shandong Province, University of Jinan School of medicine and Life Sciences Patentee before: University of Jinan |